The Politics of the Pharmaceutical Industry and Access to Medicines
World Pharmacy and India

Edited by
Hans Löfgren
Contents

List of Tables and Figures xiii
List of Contributors xv
List of Acronyms xvii

1. The Pharmaceutical Industry and Access to Medicines in India
   Hans Löfgren
   The Pre-1972 Product Patent Period 7
   Full TRIPS-compliance from 2005 12
   Financial and Economic Crisis and Access to Medicines for All 17

2. Challenges of Regulation of Medicines in India
   S. Srinivasan and Anant Phadke
   Price Regulation 25
   Weeding Out of Irrational Medicines: A Necessary Complement to Price Control 31
   Law on Banning Irrational Medicines 35
   Towards Ethical Marketing and Promotion of Medicines 38
   Promoting Transparency and Declarations of Conflict of Interest 40
   General Review of all Legislations 41
   Other Issues 42
   Conclusion 48
3. CIPLA: Patients before Patents 55
   
   Neelam Raaj
   
   Modest Beginnings 56
   Yusuf Hamied Living up to his Legacy 57
   India’s Patent Law 1972 58
   The Three Drug Combination: Potent Cocktail 58
   A Life-saving Offer 59
   Success Story 62
   The Road Ahead 63

4. Systemic Failure of Regulation: The Political Economy of Pharmaceutical and Bulk Drug Manufacturing 73
   
   G. Vijay
   
   The Regulation of Industrial Pollution 75
   Structure and Methodology 80
   Structures of the Value Chains in the Rural Economy 82
   Pathways of Pollution in the Dairy Industry 83
   Regulatory Checks on Pathways in Value Chains 87
   Final Observations 97

5. TRIPS Flexibilities and Access to Patented Medicines in India 108
   
   Narayanan Lalitha
   
   Use of Trips Flexibilities 109
   Exemptions from Patentability 109
   Future Options 126

6. India’s Free Trade Agreements: Implications for Access to Medicines in India and the Global South 134
   
   Kajal Bhardwaj
   
   Introduction 134
   TRIPS Compliance: Using the Doha Declaration in India 136
   India’s FTA Negotiations: An Overview 139
   FTAs and Access to Medicines: Key Concerns 142
   Intellectual Property Provisions 143
   Investment (or Investor Protection) Measures 155
   Regulatory Harmonization 159
### Contents

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Government of India's Position</td>
<td>160</td>
</tr>
<tr>
<td>FTAs, TRIPS and the Right to Health</td>
<td>161</td>
</tr>
<tr>
<td>Conclusion</td>
<td>164</td>
</tr>
<tr>
<td>7. At any Price? Boehringer Ingelheim, Bayer HealthCare and Baxter in India</td>
<td>176</td>
</tr>
<tr>
<td>Christiane Fischer and Claudia Jenkes</td>
<td></td>
</tr>
<tr>
<td>The Examined Companies</td>
<td>178</td>
</tr>
<tr>
<td>How Good are the Drugs Supplied by these Companies?</td>
<td>180</td>
</tr>
<tr>
<td>What about Access?</td>
<td>185</td>
</tr>
<tr>
<td>Drug Treatment in the NGO, Private and Public Sectors</td>
<td>187</td>
</tr>
<tr>
<td>Research and Patents</td>
<td>189</td>
</tr>
<tr>
<td>Marketing and Business Behaviour</td>
<td>190</td>
</tr>
<tr>
<td>Conclusion</td>
<td>193</td>
</tr>
<tr>
<td>8. Trends and Prospects for India as a Global Generic Player</td>
<td>198</td>
</tr>
<tr>
<td>Deepak Kumar Jena and Poduri Balaram</td>
<td></td>
</tr>
<tr>
<td>Introduction</td>
<td>198</td>
</tr>
<tr>
<td>Regulatory Status of India in World Generics</td>
<td>199</td>
</tr>
<tr>
<td>Markets</td>
<td></td>
</tr>
<tr>
<td>India’s Bilateral Trade in Pharmaceutical Products</td>
<td>207</td>
</tr>
<tr>
<td>Outlook for the Indian Pharmaceutical Industry</td>
<td>211</td>
</tr>
<tr>
<td>TRIPS and the Future of the Indian Pharmaceutical Industry</td>
<td>218</td>
</tr>
<tr>
<td>Industry</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>220</td>
</tr>
<tr>
<td>9. The Indian Patent Law and Access to Antiretroviral Drugs in Sub-Saharan Africa</td>
<td>225</td>
</tr>
<tr>
<td>Christiane Fischer</td>
<td></td>
</tr>
<tr>
<td>TRIPS and Public Health</td>
<td>226</td>
</tr>
<tr>
<td>Compulsory Licensing</td>
<td>227</td>
</tr>
<tr>
<td>Parallel Imports</td>
<td>229</td>
</tr>
<tr>
<td>The Scope of Patentability</td>
<td>230</td>
</tr>
<tr>
<td>Indian Patent Law</td>
<td>233</td>
</tr>
<tr>
<td>African Patent Laws</td>
<td>236</td>
</tr>
<tr>
<td>The Impact of the Patent Status in India on Access in Sub-Saharan Africa</td>
<td>236</td>
</tr>
</tbody>
</table>
Lacking Access to Patented Radical Innovative Antiretrovirals 240
Patents Matter 241

10. Accessing Medicines in Developing Economies 248

Tu Thanh Nguyen
Intersection between IPRs and Competition Law 251
Refusal to Licence Pharmaceutical Patents in South Africa 254
Some Considerations 258
Abbott’s Withdrawal of Medicine Registration Applications in Thailand 262
Exclusive Distribution and the High Prices of Medicines in Vietnam 263
Indian Perspective 265
Concluding Remarks 267

11. The Politics of AIDS Treatment in Brazil 274

André de Mello e Souza
Introduction 274
The Strategy of Local Generic Production 276
Challenges to the Sustainability of an Inclusive AIDS Treatment Policy 284
Restricting Patent Rights to Reduce ARV Costs 289
Conclusions 293


Philip Soos and Hans-Löfgren
Problems with the Patent System 306
Alternative Mechanisms for Financing R&D 311
Conclusion 322

13. Post-script 328

Hans Löfgren

Glossary 337